https://www.selleckchem.com/products/m344.html
e., monoclonal VIP/PACAP antibodies) will likely lead to importance novel treatment approaches in these diseases. Recent insights from studies of VIP/PACAP and their receptors in both CNS disorders (migraine, posttraumatic stress disorder, addiction [drugs, alcohol, smoking]) and inflammatory disorders [such as rheumatoid arthritis] are suggesting new treatment approaches. The elucidation of the importance of VIP/PACAP system in these disorders combined recent development of specific drugs acting on this system (i.e., monoclonal VIP/PACAP
Like
Comment
Share
